CFO appointment
Olema Pharmaceuticals, Inc. appoints Jason O'Byrne as CFO
Olema Pharmaceuticals, Inc. reported in a Form 8-K filed August 13, 2026 that Jason O'Byrne was appointed Chief Financial Officer, principal financial officer and principal accounting officer, effective August 11, 2026.
In the filing's words
On August 13, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced the appointment of Jason O’Byrne as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company (the “Board”) on July 28, 2026 and effective as of August 11, 2026 (the “Effective Date”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Olema Pharmaceuticals, Inc. (OLMA) |
|---|---|
| Event | Appointment |
| Incoming | Jason O'Byrne |
| Title in the filing | Chief Financial Officer, principal financial officer and principal accounting officer |
| Effective | August 11, 2026 |
| 8-K filed | August 13, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Executive Vice President and Chief Financial Officer, Vir Biotechnology, Inc. |
| SEC CIK | 0001750284 |
Olema Pharmaceuticals, Inc. reported this change in a Form 8-K, Item 5.02, filed August 13, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Jason O'Byrne? Send a correction with the primary source.